Benidipine is a dihydropyridine calcium antagonist that has been used clinically as an antihypertensive and antianginal agent. It is used clinically as a racemate, containing the (؊)-␣ and (؉)-␣ isomers of benidipine. This study was performed to elucidate the metabolism of benidipine and its enantiomers in human liver microsomes (HLMs) and to characterize the cytochrome P450 (P450) enzymes that are involved in the metabolism of benidipine. Human liver microsomal incubation of benidipine in the presence of NADPH resulted in the formation of two metabolites, N-desbenzylbenidipine and dehydrobenidipine. The intrinsic clearance (CL int ) of the formation of N-desbenzylbenidipine and dehydrobenidipine metabolites from (؊)-␣ isomer was similar to those from the (؉)-␣ isomer (1.9 ؎ 0.1 versus 2.3 ؎ 2.3 l/min/pmol P450 and 0.5 ؎ 0.2 versus 0.6 ؎ 0.6 l/min/pmol P450, respectively). Correlation analysis between the known P450 enzyme activities and the rate of the formation of benidipine metabolites in the 15 HLMs showed that benidipine metabolism is correlated with CYP3A activity. The P450 isoform-selective inhibition study in liver microsomes and the incubation study of cDNA-expressed enzymes also showed that the N-debenzylation and dehydrogenation of benidipine are mainly mediated by CYP3A4 and CYP3A5. The total CL int values of CYP3A4-mediated metabolite formation from (؊)-␣ isomer were similar to those from (؉)-␣ isomer (17.7 versus 14.4 l/min/pmol P450, respectively). The total CL int values of CYP3A5-mediated metabolite formation from (؊)-␣ isomer were also similar to those from (؉)-␣ isomer (8.3 versus 11.0 l/min/pmol P450, respectively). These findings suggest that CYP3A4 and CYP3A5 isoforms are major enzymes contributing to the disposition of benidipine, but stereoselective disposition of benidipine in vivo may be influenced not by stereoselective metabolism but by other factors.
Benidipine is a highly potent dihydropyridine calcium antagonist that is used clinically as a racemate. This agent shows slow onset and long-lasting antihypertensive and antianginal effects owing to the blockade of calcium ion entry to smooth muscle Yamada et al., 1990) . It is currently in clinical use for the treatment of hypertension as a single daily medication (2-8 mg) . Like other dihydropyridine calcium antagonists (except nifedipine and mepirodipine), benidipine has asymmetric carbons both in the 1,4-dihydropyridine ring and in the side chain of the benzylpiperidine ring. This drug is a racemate consisting of two optical isomers [(ϩ)-␣ and (Ϫ)-␣ isomer] of the four possible optical isomers because the other isomers are removed during the crystallization step on synthesis (Kobayashi and Kobayashi, 1998) . The (ϩ)-␣ isomer was 30-to 100-fold more active than the (Ϫ)-␣ isomer in terms of the antihypertensive effect after i.v. administration to the spontaneously hypertensive rat (Muto et al., 1988) .
Pharmacokinetic studies in rats (Kobayashi and Kobayashi, 1998 ) and humans (Kobayashi et al., 1997) have shown that benidipine is well absorbed but exhibits low absolute bioavailability as a result of marked first-pass metabolism. Accordingly, various metabolites were identified in these species (Kobayashi et al., 1997; Kobayashi and Kobayashi, 1998) . In our previous study involving human plasma, we found that the plasma concentrations of (ϩ)-␣-benidipine were consistently higher than those of the (Ϫ)-␣ isomer after dosing of 8 mg of racemic benidipine (Kang et al., 2005) . The C max and area under the curve to infinity values of (ϩ)-␣-benidipine (1.47 Ϯ 0.75 ng/ml and 2.48 Ϯ 1.18 ng ⅐ h/ml, respectively) were higher than those of (Ϫ)-␣-benidipine (0.75 Ϯ 0.46 ng/ml and 1.34 Ϯ 0.48 ng ⅐ h/ml, respectively) by 1.96-and 1.85-fold, respectively ( p Ͻ 0.001). However, the mechanism of stereoselective disposition of benidipine in vivo has not yet been elucidated.
In the present study, we examined the metabolic pathways of benidipine using human liver microsomal fractions and in particular identified the cytochrome P450 (P450) isoforms responsible for each monitoring the transitions of m/z 416 3 315 for N-desbenzylbenidipine (collision energy 24 eV), 504 3 91.2 for dehydrobenidipine (collision energy 95 eV), and 409 3 238 for amlodipine (IS, collision energy 15 eV). Peak areas for all the components were automatically integrated using Analyst software (version 1.4, Applied Biosystems). The lower limits of quantification for the two metabolites were 0.2 nM. The interassay precision for the analyte was less than 15%.
Chemical Inhibition Studies with HLMs. The inhibitory effects of known P450 isoform-selective inhibitors on the formation of N-desbenzylbenidipine and dehydrobenidipine were evaluated to determine the P450 isoform(s) involved in the metabolic pathway. The formation ratio of N-desbenzylbenidipine and dehydrobenidipine from benidipine racemate or enantiomers was determined from the reaction mixtures incubated in the presence or absence of known P450 isoform-selective inhibitors (Kim et al., 2006; Lee et al., 2006) . The P450 isoform-selective inhibitors used were furafylline (10 M) for CYP1A2, coumarin (100 M) for CYP2A6, triethylenethiophosphoramide (5 M) for CYP2B6, montelukast (0.1 M) for CYP2C8, sulfaphenazole (10 M) for CYP2C9, S-benzylnirvanol (1 M) for CYP2C19, quinidine (10 M) for CYP2D6, diethyldithiocarbamate (10 M) for CYP2E1, ketoconazole (1 M) for CYP3A, and azamulin (5 M) for CYP3A. SKF 525-A (100 M) was also used as nonselective P450 inhibitor. FMO was heat-deactivated by incubating tubes (0.1 mg of microsomal protein and phosphate buffer) without NADPH-generating system in a water bath set at 45°C for 5 min to elucidate whether FMO is responsible for benidipine metabolism. Except for the addition of P450 isoform-selective inhibitors, all the other incubation conditions were similar to those described previously (Shin et al., 1999 (Shin et al., , 2002 .
Correlation Experiments. Benidipine (5 M) was incubated with microsomes from 15 different livers to test the correlation of benidipine metabolism with the activity of individual P450s. The activities of each P450 isoform were determined using mixture incubation and tandem mass spectrometry, as described previously (Kim et al., 2005) . Isoform-specific reaction markers were used to determine the activity of each P450: phenacetin O-deethylation (CYP1A2), coumarin 7-hydroxylation (CYP2A6), bupropion hydroxylation (CYP2B6), paclitaxel 6␣-hydroxylation (CYP2C8), tolbutamide 4-methylhydroxylation (CYP2C9), S-mephenytoin 4-hydroxylation (CYP2C19), dextromethorphan O-demethylation (CYP2D6), chlorzoxazone 6-hydroxylation (CYP2E1), and midazolam 1Ј-hydroxylation (CYP3A). The correlation coefficients between the formation rates of benidipine metabolites and the activity of each P450 isoform in the different HLMs were calculated by parametric regression analysis (SAS version 8.01, SAS Institute Inc., Cary, NC). A p value less than 0.05 was considered statistically significant. Data Analysis. Results are expressed as mean Ϯ S.D. of estimates obtained from four different liver microsomes in duplicate experiments. In the microsomal incubation studies, the apparent kinetic parameters of benidipine biotransformation (K m and V max ) were determined by fitting a one-enzyme
The calculated parameters were the maximum rate of formation (V max ), the Michaelis constant (apparent K m ), the intrinsic clearance dmd.aspetjournals.org (CL int ϭ V max /apparent K m ), and Hill coefficient (n). Calculations were performed using WinNonlin software (Pharsight, Mountain View, CA). The percentages of inhibition were calculated by the ratio of the amounts of metabolites formed with and without the specific inhibitor. In the incubation study using cDNA-expressed P450 isoforms, a Hill equation model was fitted to the unweighted data on the formation rate of both metabolites to estimate the enzyme kinetic parameters. The models that best fit were selected based on the dispersion of residuals and standard errors of the parameter estimates.
Contributions of each cytochrome to benidipine metabolism were normalized for mean values of the relative abundance of individual cytochromes in the liver (Rodrigues, 1999) . In brief, the reaction rates measured with individual cDNA-expressed P450 isoforms were normalized with respect to the nominal specific content of the corresponding P450 in native HLMs. In this study, we adapted the data of immunologically determined P450 isoform liver contents reported by other researchers (Wrighton et al., 1990; Shimada et al., 1994) , i.e., 4.0% for CYP2A6, 1.5% for CYP2D6, 23.0% for CYP3A4, and 5.8% for CYP3A5. In turn, the normalized rates for each cDNA-expressed P450 were summed, yielding a total normalized rate (ϭ Αf i ⅐ V i ), and the normalized rate for each P450 isoform (ϭ f i ⅐ V i ) was expressed as a percentage of the net reaction rate (ϭ 100 ⅐ f i ⅐ V i /Αf i ⅐ V i , where f i indicates the fraction of each P450 isoform content in the human liver).
Results

Identification of Benidipine Metabolites in HLMs.
After the incubations of benidipine with HLMs in the presence of an NADPHgenerating system, the benidipine and its two metabolites (N-desbenzylbenidipine and dehydrobenidipine) were profiled, characterized, and tentatively identified using LC/MS analysis ( Fig. 1) . Other metabolites that were observed in plasma, urine, and feces after p.o. administration of benidipine to humans were not found in the human liver microsomal incubation sample. LC/MS/MS analysis of the unchanged benidipine and its two metabolites produced the informative and prominent product ions for structural elucidation. MS/MS spectrum of benidipine, having a protonated molecular ion [M ϩ H] ϩ at m/z 506, showed major fragment ions at m/z 174 (the loss of benzylpiperidine group), m/z 315 (carboxyl group cleavage), and m/z 91 (the loss of benzyl group) (Fig. 2) . Major metabolites N-desbenzylbenidipine and dehydrobenidipine were identified by cochromatography and the MS/MS spectral data of the authentic compounds (Fig. 2) . The mass spectrum of N-desbenzylbenidipine has a protonated molecular ion peak [M ϩ H] ϩ at m/z 416, suggesting loss of benzyl molecule from benidipine ([M ϩ H] ϩ , m/z 506). The MS/MS spectrum of N-desbenzylbenidipine also showed a fragmentation pattern similar to the parent compound (Fig. 2) . Dehydrobenidipine gave an [M ϩ H] ϩ molecular ion at m/z 504, suggesting loss of hydrogen atoms from the parent compound. The MS/MS spectrum of dehydrobenidipine by fragmenting m/z 504 through collision gave the characteristic daughter ions at m/z 91, 174, 285, and 313, suggesting the possible oxidation of the dihydropyridine ring (Fig. 2) .
Identification of the P450 Isoforms Involved in the Metabolism of Benidipine. Human liver microsomal incubation of benidipine in the presence of NADPH resulted in the formation of dehydrobenidipine and N-desbenzylbenidipine. Heat inactivation of the FMO activity did not inhibit benidipine metabolism, whereas SKF 525-A did inhibit benidipine metabolism (Table 1 ), suggesting that P450 is the enzyme responsible for benidipine metabolism. The rates of formation of metabolite were proportional to incubation times up to 10 min and protein concentration up to 0.3 mg/ml at 5 min. A P450 isoform- dmd.aspetjournals.org Downloaded from selective inhibition study was performed to evaluate which P450 isoforms are involved in the metabolism of benidipine in HLMs (Fig.  3) . Among the 10 inhibitors tested, ketoconazole, a well known CYP3A-selective inhibitor (Bourrie et al., 1996) , inhibited N-desbenzylbenidipine and dehydrobenidipine formation from benidipine. After treatment of 1 M ketoconazole, the level of N-desbenzylbenidipine and dehydrobenidipine formation from benidipine enantiomers markedly decreased to 7 to 17% and 26 to 31% of that in the controls, respectively. It is difficult to explain why ketoconazole showed partial inhibition on dehydrobenidipine formation of benidipine with the present data. However, CYP3A has multiple binding sites and therefore sometimes shows partial inhibition (partial inhibition of erythromycin N-demethylation by testosterone in microsomes) (Wang et al., 1997) . Therefore, further studies would be needed to clarify partial inhibition by ketoconazole. Benidipine metabolism was also inhibited by azamulin, another CYP3A inhibitor (Streel et al., 2002) . Correlations between the rate of benidipine metabolism and the activities of P450s in HLMs are summarized in Table 2 . The formation rates of dehydrobenidipine and N-desbenzylbenidipine from benidipine were significantly correlated with the activity of CYP3A (Fig. 4) .
Dehydrobenidipine and N-desbenzylbenidipine formation from benidipine and its enantiomers (1 and 10 M) was also studied using the human cDNA-expressed P450 isoforms CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 (Fig. 5 ). CYP3A4 and CYP3A5 metabolized benidipine more efficiently than any other P450, with little contribution of CYP2A6 and CYP2D6. To determine the relative contributions of four P450 isoforms to benidipine metabolism in HLMs, we estimated the percentage of the net reaction rate from the abundanceadjusted simulation of each P450 isoform in HLMs. This simulation also shows that CYP3A is the major P450 enzyme responsible for benidipine metabolism. The percentage of net reaction by CYP2A6 and CYP2D6 is lower than 3.6 and 2.3%, respectively, whereas that by CYP3A is higher than 90.0%. The levels of involvement of other recombinant P450 isoforms in the formation of benidipine metabolites were negligible.
Enzyme Kinetic Analysis. The formation of both N-desbenzyl and dehydro metabolites did not show stereoselective metabolism on incubation of human liver microsomal preparations (Fig. 6) . Under the experimental conditions used, the metabolism of benidipine by HLMs was best-fitted by a Hill equation (Table 3 ). The fitting of the data to the Michaelis-Menten expression of a two-enzyme model did not significantly improve the regression, as compared with fitting of the data of a one-enzyme model. The sums of the formation CL int of both metabolites were 2.9 and 2.4 l/min/pmol P450 for (ϩ)-␣-benidipine and (Ϫ)-␣-benidipine, respectively, indicating nonstereoselectivity in the metabolism of benidipine.
Next, we examined the enzyme kinetic parameters for the formation of N-desbenzylbenidipine and dehydrobenidipine from benidipine enantiomers (0 -200 M) on incubation with cDNA-expressed human CYP3A4 and CYP3A5 (Fig. 7) . Under the experimental conditions used, the metabolism of benidipine by these P450 isoforms was also best described by a Hill equation (Table 4) 
TABLE 2
Correlation of formation rates of dehydrobenidipine and N-desbenzylbenidipine from benidipine (5 M) with the P450 maker activities in HLMs (n ϭ 15)
Data were analyzed using the parametric correlation test (Pearson r). The activity of each isoform was determined using the respective specific substrate probe reaction, as described previously (Kim et al., 2005) . dmd.aspetjournals.org metabolized both benidipine enantiomers to N-desbenzylbenidipine and dehydrobenidipine (Table 4 ). The CYP3A4-catalyzed Ndebenzylation of benidipine enantiomers showed lower K m and higher V max than those of the dehydrogenation, resulting in a higher CL int of N-desbenzylbenidipine formation than dehydrobenidipine formation (12.3-16.1 versus 1.6 -2.1 l/min/pmol CYP3A4, respectively). CYP3A5 also showed similar tendency as in the case of CYP3A4.
Discussion
The metabolism studies of benidipine have been reported for various organisms such as rats and humans (Kobayashi et al., 1988a (Kobayashi et al., ,b, 1997 . As the result of previous research, a lot of metabolites were identified, and major metabolic pathways were N-debenzylation, dehydrogenation, ester hydrolysis, decarboxylation, and so on. In the present study, we determined that the major metabolites of human liver microsomal incubation were N-desbenzylbenidipine and an oxidized metabolite of the dihydropyridine ring (dehydrobenidipine) (Fig. 1) . Benidipine was metabolized by HLMs in the presence of an NADPH-generating system but was not metabolized in the absence of NADPH. This result suggests that benidipine metabolism in humans is P450-dependent.
Owing to a common structural feature, N-debenzylation and oxi- dmd.aspetjournals.org dation of dihydropyridine ring pathways have been consistently reported as routes for other dihydropyridine calcium antagonists such as barnidipine (Teramura et al., 1997b) and efonidipine (Nakabeppu et al., 1995) . Estimated intrinsic clearance, based on the V max /K m for the two primary metabolic pathways, suggests N-debenzylation is the more dominant metabolic pathway of benidipine than oxidation of the dihydropyridine ring. The CL int of both benidipine enantiomers indicated that N-desbenzyl metabolite formation contributes to 79% of benidipine metabolism and dehydro metabolite formation contributes to 21% (Table 3) . Therefore, it is considered that benidipine is catalyzed by the same mechanism as that proposed for other structural analogs (Guengerich and Bocker, 1988) . Our present findings were further supported by the reports that P450s catalyze oxidation of the dihydropyridine ring (Baarnhielm and Hansson, 1986) and that nifedipine and felodipine, typical 1,4-dihydropyridine-type calcium antagonists, are oxidized by the CYP3A4 isoform (Bocker and Guengerich, 1986; Guengerich et al., 1991) . The N-debenzylation pathway was specifically dependent on a particular substituent present in benidipine, and barnidipine, a similar structural analog, is also metabolized by the CYP3A enzyme (Teramura et al., 1997a) .
We provide evidence that benidipine metabolism is catalyzed by the CYP3A subfamily. First, formation rates of N-desbenzylbenidipine and dehydrobenidipine were inhibited (68 -78%) by ketoconazole and azamulin, potent CYP3A-selective inhibitors (Fig. 3) . Second, expressed human CYP3A4 and CYP3A5 metabolized benidipine to its two metabolites, whereas other P450 isoforms did not (Fig. 5) . Third, midazolam 1Ј-hydroxylation activity (a marker of CYP3A activity) in 15 individual HLMs exhibited high correlation with the formation rate of the metabolites (r ϭ 0.66 -0.80) ( Table 2 ). The significant correlation we observed between the activity of CYP1A2 and benidipine metabolism in the panel of HLMs tested may not be caused by the actual involvement of CYP1A2 in benidipine metabolism. Because our inhibition and recombinant experiments do not support a significant role of CYP1A2 in benidipine metabolism, the observed significant correlation between benidipine metabolism and CYP1A2 is probably derived from the significant correlation between the activity of CYP1A2 and CYP3A (Pearson r ϭ 0.57; p ϭ 0.02) in the bank of human livers tested. It is interesting that the two major metabolic pathways of benidipine are catalyzed by the same CYP3A subfamily despite their different metabolic mechanisms, but this may be explained by the fact that CYP3A has a broad substrate specificity (Spatzenegger and Jaeger, 1995; Patki et al., 2003) . Taken together, these results suggest that CYP3A is the major enzyme involved in the metabolism of benidipine at concentrations in the usual experimental ranges.
In general, the stereoselective pharmacokinetics of dihydropyridine 
TABLE 4
Mean enzyme kinetic parameters of the formation of N-desbenzylbenidipine and dehydrobenidipine from benidipine enantiomers from the cDNA-expressed P450s calcium antagonists, such as felodipine, nimodipine, nitrendipine, and nilvadipine, in animals and humans has been extensively reported (Niwa et al., 1988; Soons et al., 1993) and reviewed (Tokuma and Noguchi, 1995; Inotsume and Nakano, 2002) . The stereoselective pharmacokinetics can be explained by the rate-limiting step of a single P450 enzyme and similar stereoselectivity for these structurally related drugs (Niwa et al., 1989; Eriksson et al., 1991) . At present, only limited pharmacokinetic data of the benidipine enantiomers are available. The preliminary data from a study in humans (Tokuma and Noguchi, 1995; Kang et al., 2005) suggest that the plasma concentrations of the (ϩ)-␣ enantiomer were higher than those of the (Ϫ)-␣ enantiomer. Therefore, we evaluated the possibility of enantioselective metabolism of benidipine using HLMs and recombinant P450 isoforms as examples of felodipine (Eriksson et al., 1991) and nilvadipine (Niwa et al., 1989) . In this in vitro study, however, no significant differences were found for the estimated Michaelis-Menten parameters V max , K m , or CL int (Table 3 ). Enzyme kinetic study using cDNA-expressed CYP3A4 and CYP3A5 also did not show any stereoselective differences on benidipine metabolism (Table 4) . Considering no enantioselective metabolism of benidipine in this in vitro study, the higher plasma levels of (ϩ)-␣-benidipine than (Ϫ)-␣-benidipine could be caused by enantioselectivity in plasma protein binding and/or by the enantioselectivity in the absorption via drug transporters such as P-glycoprotein. For example, the free fraction value of semotiadil (R isomer), a calcium antagonist, is 0.7 times less than that of levosemotiadil (S isomer) in human plasma (Rodriguez Rosas et al., 1997) . However, the protein binding of benidipine in human serum was almost constant at about 99% over a concentration range of 1 to 10,000 ng/ml (Kobayashi and Kobayashi, 1999) . Therefore, the effect of enantioselective protein binding on enantioselective disposition of benidipine would not be important.
In conclusion, this study shows that the primary metabolic pathway of benidipine in HLMs is N-debenzylation and oxidative dehydrogenation. The P450 isoform-specific chemical inhibition study, correlation study, and incubation study of cDNA-expressed P450 enzymes showed that CYP3A4 and CYP3A5 were responsible for the formation of two metabolites from benidipine. In addition, benidipine did not show stereoselectivity on metabolism. Therefore, detailed studies for elucidation of the mechanism of enantioselective disposition of benidipine in vivo are required.
